Clinical Course and Side Effects of Anti-IgE Monoclonal Antibody in Patients with Severe Persistent Asthma

Yalcin A. D. , Bisgin A. , Cetinkaya R., Yildirim M., Gorczynski R. M.

CLINICAL LABORATORY, cilt.59, ss.71-77, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 59
  • Basım Tarihi: 2013
  • Doi Numarası: 10.7754/clin.lab.2012.120406
  • Sayfa Sayıları: ss.71-77


Background: Omalizumab, a recombinant humanized monoclonal antibody to IgE, is recommended as a new option for the treatment of severe persistent allergic asthma. The purpose of this study is to assess the effects omalizumab treatment on life quality and its side effects in severe persistent asthma patients.